GEN Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
EN
13/10/2020

Underlying

GENGenmab A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genmab A/S

 PRESS RELEASE
Free
GEN GENMAB A/S

Transactions with shares and linked securities in Genmab A/S made by m...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; February 27, 2026 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf ...

February 27, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Grant of Restricted Stock Units to Management and Employees and Grant ...

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; February 27, 2026 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 587,495 restricted stock units to members of management and employees of the Company as well as the Company's subsidiaries and 455,004 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK...

February 27, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Genmab to Participate in Upcoming Investor Conferences

Genmab to Participate in Upcoming Investor Conferences Media ReleaseCOPENHAGEN, Denmark; February 25, 2026 (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in March 2026:  TD Cowen 46th Annual Healthcare Conference in Boston on March 3, 2026, 9:10 AM EST (3:10 PM CET)Leerink Global Healthcare Conference in Miami on March 10, 2026, 8:40 AM EDT (1:40 PM CET)Barclays 28th Annual Global Healthcare Conference in Miami on March 11, 2026, 1:30 PM EDT (6:30 PM CET) The live and archived webcast of the p...

February 25, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; February 24, 2026 – (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 710 shares at DKK 1,147.50,239 shares at DKK 1,155.00,1,527 shares at DKK 1,161.00,1,183 shares at DKK 1,334.50,5,391 shares at DKK 1,362.50, and3...

February 24, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; February 23, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than March 31, 2026. The following transactions were executed under the program from February 18 to February 20, 2026:  No. of sharesAverage price ...

February 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch